Agnese Fabbri - Concepedia

Author

Agnese Fabbri

Also Known As

A Fabbri, A. Fabbri, A., Fabbri, Agnese Fabbri, M Fabbri, M. A. Fabbri, M. Agnese Fabbri, M. Fabbri, M.A. Fabbri, MARIA AGNESE FABBRI

141

Publications

1.7K

Citations

H-Index

Concepts

All Affiliations

Ospedale di Belcolle Istituti di Ricovero e Cura a Carattere Scientifico Sapienza University of Rome Policlinico Umberto I University of Chieti-Pescara

About

Agnese Fabbri is an author at Ospedale di Belcolle specializing in medicine, oncology, and breast cancer.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	13	456
2	Health Sciences	4	4	129
3	Immunology	3	3	79
4	Cell Biology	2	2	67
5	Epidemiology	1	1	10

Agnese Fabbri

Publications

1.3K

Citations

H-Index

Page 1

	Year	Citations
Randomized Trial of Two Induction Chemotherapy Regimens in Metastatic Colorectal Cancer: An Updated Analysis Gianluca Masi, E. Vasile, Fotios Loupakis, JNCI Journal of the National Cancer Institute	2010	188
<i>KRAS</i> mutations affect prognosis of non-small-cell lung cancer patients treated with first-line platinum containing chemotherapy Mirko Marabese, Monica Ganzinelli, Marina Chiara Garassino, Oncotarget	2015	87
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial Sabino De Placido, Ciro Gallo, Michelino De Laurentiis, The Lancet Oncology Endocrine OncologyBreast OncologyMedicinePharmacologyEndocrine-sensitive Breast Cancer	2018	86
Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study Giulia Bon, Laura Pizzuti, Valentina Laquintana, Journal of Experimental & Clinical Cancer Research	2020	72
A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience Patrizia Vici, Laura Pizzuti, Andrea Michelotti, Oncotarget	2017	68
Adjuvant zoledronic acid and letrozole plus ovarian function suppression in premenopausal breast cancer: HOBOE phase 3 randomised trial Francesco Perrone, Michelino De Laurentiis, Sabino De Placido, European Journal of Cancer Ovarian Function SuppressionOncologyBreast OncologyAdjuvant Zoledronic AcidMedicine	2019	68
T-DM1 and brain metastases: Clinical outcome in HER2-positive metastatic breast cancer Alessandra Fabi, Daniele Alesini, Enrichetta Valle, The Breast Neuro-oncologyBreast OncologyBrain MetastasesMedicinePathology	2018	55
TAILOR: Phase III trial comparing erlotinib with docetaxel in the second-line treatment of NSCLC patients with wild-type (wt) EGFR. Marina Chiara Garassino, Olga Martelli, Anna Bettini, Journal of Clinical Oncology Surgical OncologyCancer ManagementPathologyPharmacotherapySecond-line Treatment	2012	54
Chemosensitivity profile assay of circulating cancer cells: prognostic and predictive value in epithelial tumors Paola Gazzaniga, Giuseppe Naso, Angela Gradilone, International Journal of Cancer Breast OncologyImmunologyPathologyPredictive ValueCancer Biology	2009	50
Adjuvant Aromatase Inhibitor Therapy in Early Breast Cancer: What Factors Lead Patients to Discontinue Treatment? Luca Moscetti, Agnese Fabbri, Isabella Sperduti, Tumori Journal	2015	49

Page 1